权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Placental-like alkaline phosphatase in testicular tumor

睾丸肿瘤中的胎盘样碱性磷酸酶

基本信息

批准号：
01570883
负责人：
KOSHIDA Kiyoshi
金额：
$ 1.34万
依托单位：
Kanazawa University
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (C)
财政年份：
1989
资助国家：
日本
起止时间：
1989 至 1991
项目状态：
已结题

项目摘要

The role of PLAP-like as a tumor marker was evaluated in 62 cases of testicular germ cell tumors. Positive rates in different histology as well as stages were as follows ; seminoma, stage I : 42%, stages II-III, 90%, nonseminoma, stage I : 17%, stages II-III : 44%. Serum PLAP-like values in stages II-III were significantly higher than those in stage I. Tissue PLAP-like concentrations in 32 seminomas and 15 nonseminomas were also investigated. Significant differences in PLAP-like concentrations were disclosed between seminoma tissues and nonseminoma tissues as well as between the cases with elevated serum levels and the cases with normal serum levels. Serum values in stage I turned to normal within a week after orchiectomy. Half-life in the circulation was calculated at 2 days. Four out of 93 cases(4.3%), 17 of 594 samples(2.9%)in a follow-up study were regarded as false positive. Thus PLAP-like appears to be a useful marker for seminoma.To investigate a potential use of an anti-PLAP monoclonal antibody for detecting tumors, HPMS-1 MAb labeled with I-125 was injected to athymic mice bearing tumors producing PLAP. Although accumulation rate(%dose/g tissue)was gradually decreased in the tumor, clearance of the MAb in other organs were more rapidly. Thereby an increase of tumor/organ ratio with time was observed, resulted in a clear tumor imaging after 9 days of injection. PLAP concentrations in the transplanted tumors were lower than those of primary seminomas or metastatic lymphnodes of seminoma. Therefore a potential use of the anti-PLAP MAb(HPMS-1)for detecting metastatic lesion of seminoma could be expected.

对62例睾丸生殖细胞肿瘤的PLAP样蛋白作为肿瘤标志物的作用进行了评价。不同组织学类型和分期的阳性率如下：腺瘤，I期：42%，II-III期：90%，非腺瘤，I期：17%，II-III期：44%。Ⅱ ~ Ⅲ期患者血清PLAP样值明显高于Ⅰ期患者。组织PLAP样浓度在32例乳腺癌和15例非乳腺癌也进行了研究。PLAP样浓度的显着差异之间的肿瘤组织和非肿瘤组织，以及与血清水平升高的情况下，与正常血清水平的情况下，披露。在第一阶段的血清值在睾丸切除术后一周内恢复正常。循环中的半衰期计算为2天。在93例病例中有4例（4.3%），在随访研究的594份样本中有17例（2.9%）被认为是假阳性。为了研究抗PLAP单克隆抗体用于检测肿瘤的潜在用途，将I-125标记的HPMS-1单克隆抗体注射到携带产生PLAP的肿瘤的无胸腺小鼠中。尽管肿瘤中的蓄积率（%剂量/g组织）逐渐降低，但MAb在其他器官中的清除更快。因此，观察到肿瘤/器官比随时间增加，导致注射9天后清晰的肿瘤成像。移植瘤组织中PLAP浓度低于原发瘤和转移淋巴结。因此，抗PLAP单克隆抗体（HPMS-1）在检测乳腺癌转移灶方面具有潜在的应用前景。